Bone: Osteoporosis therapy-Time to consider renal function

Nature Reviews Endocrinology

Volumn 7, Issue 8, 2011, Pages 440-441

  Cannata Andía, Jorge B ^a   Gómez Alonso, Carlos ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB;

CHRONIC KIDNEY DISEASE; DRUG EFFICACY; DRUG SAFETY; FRAGILITY FRACTURE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; PATIENT SAFETY; POST HOC ANALYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REHABILITATION; SHORT SURVEY;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; OSTEOPOROSIS; TIME FACTORS;

EID: 79960835582     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2011.114     Document Type: Short Survey

References (9)

1. Jamal, S. et al. The effects of denosumab on fracture and bone mineral density by level of kidney function. J. Bone Miner. Res. doi:10.1002/jbmr.403.
2. Jamal, S. A. et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J. Bone Miner. Res. 22, 503-508 (2007). (Pubitemid 47457426)
3. Miller, P. D. et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J. Bone Miner. Res. 20, 2105-2115 (2005). (Pubitemid 41698774)
4. Ishani, A., et al. The effect of raloxifene treatment in postmenopausal women with CKD. J. Am. Soc. Nephrol. 19, 1430-1438 (2008).
5. Miller, P. D., Schwartz, E. N., Chen, P., Misurski, D. A. & Krege, J. H. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos. Int. 18, 59-68 (2007). (Pubitemid 44885496)
6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. 76 (Suppl. 113), S1-S130 (2009).
7. Gómez-Alonso, C. et al. Vitamin D status and secondary hyperparathyroidism: the importance of 25-hydroxyvitamin D cut-off levels. Kidney Int. 63 (Suppl. 85), S44-S48 (2003). (Pubitemid 36605861)
8. Levin, A. et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 71, 31-38 (2007). (Pubitemid 44967731)
9. Block, J. et al. A single dose study of denosumab in patients with various degrees of renal impairment [abstract]. Page 6. In National Kidney Foundation 2010 Spring Clinical Meeting Abstracts. http://www.kidney.org/news/ meetings/clinical/pdf/CM10-abstracts.pdf.